What are the recommended dosing regimens for medications used to treat an acute gout flare and for long‑term urate‑lowering therapy?

Medication Dosing for Gout: Acute Flares and Urate-Lowering Therapy

Acute Gout Flare Treatment

Colchicine

For acute gout flares, use low-dose colchicine: 1.2 mg initially, followed by 0.6 mg one hour later. 1

• This low-dose regimen is equally effective as high-dose colchicine (1.2 mg followed by 0.6 mg hourly for 6 hours) but causes significantly fewer gastrointestinal adverse effects (23% vs 77% diarrhea rate). 1
• High-dose colchicine should be avoided due to excessive toxicity without additional benefit. 1

NSAIDs

• Any NSAID at full anti-inflammatory doses is effective; no clinically important differences exist between different NSAIDs. 1
• Example: Indomethacin 50 mg three times daily for 10 days. 2
• Naproxen 250 mg twice daily is another option. 3
• NSAIDs carry gastrointestinal and renal risks, particularly with prolonged use. 1

Corticosteroids

• Oral prednisone or prednisolone 30–40 mg daily for acute flares. 4
• Systemic corticosteroids are equivalent to NSAIDs for pain reduction in acute gout. 1
• Long-term use causes dose- and duration-dependent adverse effects including hyperglycemia, immune suppression, and fluid retention. 1

---

Urate-Lowering Therapy (ULT) Dosing

Allopurinol (First-Line Agent)

Start allopurinol at ≤100 mg/day in patients with normal renal function, or ≤50 mg/day in patients with CKD stage ≥3, then titrate upward to achieve target serum urate <6 mg/dL (or <5 mg/dL if tophi present). 1, 4

Starting Doses

• Normal renal function: ≤100 mg/day 1, 4
• CKD stage ≥3: ≤50 mg/day 1, 4

Titration Strategy

• Increase by 100 mg increments weekly until target serum urate is achieved. 4
• Maximum FDA-approved dose: 800 mg/day. 1
• Most patients require doses >300 mg/day to reach target urate levels. 1

Target Serum Urate

• <6 mg/dL for all patients with gout 4
• <5 mg/dL when tophi are present 4

Febuxostat (Second-Line Agent)

Start febuxostat at ≤40 mg/day, then titrate to 80 mg/day or 120 mg/day as needed to achieve target serum urate. 1

Indications for Febuxostat

• Documented allopurinol hypersensitivity or severe cutaneous adverse reactions 4
• Failure to achieve target serum urate after titrating allopurinol to 800 mg/day 4

Dosing

• Starting dose: ≤40 mg/day 1
• Maintenance doses: 80 mg or 120 mg daily 5
• Febuxostat 80 mg and 120 mg are more effective than fixed-dose allopurinol 300 mg (53% and 62% vs 21% achieving target urate). 5

Probenecid (Alternative Uricosuric)

Start probenecid at 500 mg once or twice daily, then titrate upward as needed. 1

• Probenecid is conditionally recommended as a starting option. 1
• Avoid in CKD stage ≥3: Xanthine oxidase inhibitors (allopurinol or febuxostat) are strongly preferred over probenecid in moderate-to-severe renal impairment. 1

---

Mandatory Anti-Inflammatory Prophylaxis During ULT Initiation

All patients starting ULT must receive concomitant anti-inflammatory prophylaxis for a minimum of 3–6 months. 1, 4

Prophylaxis Options

• Colchicine: 0.6 mg once or twice daily 3, 4
• NSAIDs: Naproxen 250 mg twice daily 3
• Corticosteroids: Prednisone or prednisolone 5–10 mg daily 4

Duration

• Continue prophylaxis for 3–6 months minimum. 1, 4
• Extend prophylaxis beyond 6 months if the patient continues to experience flares. 1, 4

Rationale

• Low starting doses of ULT with prophylaxis reduce the risk of flares associated with therapy initiation. 1
• Omitting prophylaxis significantly increases early flare rates and treatment discontinuation. 4

---

Initiating ULT During an Active Flare

You may start allopurinol during an active gout flare (rather than waiting for resolution) provided appropriate anti-inflammatory treatment is given. 1, 4

Protocol

1. Treat the acute flare with full-dose anti-inflammatory therapy (colchicine, NSAID, or corticosteroid). 4
2. Start allopurinol simultaneously at low dose (100 mg daily, or 50 mg daily if CKD ≥3). 4, 2
3. Add prophylactic anti-inflammatory therapy. 4
4. Maintain prophylaxis for at least 3–6 months. 4

Evidence

• Initiating allopurinol 300 mg daily during an acute flare (with indomethacin and colchicine prophylaxis) caused no significant difference in daily pain, recurrent flares, or inflammatory markers compared to delayed initiation. 2
• This represents a paradigm shift from older teaching that required waiting for flare resolution. 4

---

Critical Pitfalls to Avoid

Starting Allopurinol at 300 mg Without Titration

• Fixed-dose allopurinol 300 mg fails to achieve target urate in most patients. 1
• Starting at high doses increases both flare risk and allopurinol hypersensitivity syndrome risk. 1, 4

Declaring Allopurinol Failure Prematurely

• Do not switch to febuxostat before titrating allopurinol to the maximum tolerated dose (up to 800 mg/day). 4

Omitting Flare Prophylaxis

• Failure to provide prophylaxis markedly increases early treatment discontinuation rates. 4

Using Febuxostat First-Line

• Febuxostat as first-line therapy contradicts guideline recommendations and incurs unnecessary cost. 1, 4

Using High-Dose Colchicine for Acute Flares

• High-dose colchicine (1.2 mg followed by 0.6 mg hourly for 6 hours) offers no additional benefit over low-dose regimens but causes significantly more gastrointestinal toxicity. 1